431 related articles for article (PubMed ID: 19531449)
1. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects of anticancer agents that target the VEGF pathway.
Chen HX; Cleck JN
Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
[TBL] [Abstract][Full Text] [Related]
3. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: VEGF as a therapeutic target for breast cancer.
Schneider BP; Sledge GW
Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
6. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
8. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
English BC; Price DK; Figg WD
Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
[No Abstract] [Full Text] [Related]
9. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenesis targeting in renal carcinomas].
Pouessel D; Culine S
Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
[TBL] [Abstract][Full Text] [Related]
11. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
12. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic therapy for breast cancer.
Nielsen DL; Andersson M; Andersen JL; Kamby C
Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
[TBL] [Abstract][Full Text] [Related]
16. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Heng DY; Mackenzie MJ; Vaishampayan UN; Bjarnason GA; Knox JJ; Tan MH; Wood L; Wang Y; Kollmannsberger C; North S; Donskov F; Rini BI; Choueiri TK
Ann Oncol; 2012 Jun; 23(6):1549-55. PubMed ID: 22056973
[TBL] [Abstract][Full Text] [Related]
17. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
18. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Horn L; Sandler AB
Clin Lung Cancer; 2009 Mar; 10 Suppl 1(Suppl 1):S7-16. PubMed ID: 19362948
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Rini BI
Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
